The KCTD9 Knockout A2780 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population for studying KCTD9 function. This product disrupts the KCTD9 gene in the A2780 human ovarian cancer cell line using CRISPR/Cas9-mediated gene targeting, generating a heterogeneous pool of cells with loss-of-function mutations. The polyclonal format avoids clonal biases and allows robust population-level analyses, making it suitable for functional genomics and biochemical studies requiring reproducible knockout phenotypes across experimental replicates.
A2780 is a well-characterized epithelial ovarian cancer cell line derived from an ovarian endometrioid adenocarcinoma. It serves as a model for high-grade serous ovarian carcinoma, featuring p53 mutation and hypersensitivity to platinum agents. This background provides a disease-relevant system to investigate molecular pathways underlying ovarian cancer progression and drug response. Using A2780 as the host line ensures that KCTD9 function is examined in a context pertinent to ovarian tumor biology.
KCTD9 is a potential substrate adaptor for the cullin-RING E3 ubiquitin ligase complex, where it likely interacts with CUL3 and RBX1 to mediate ubiquitination and proteasomal degradation of specific protein substrates. Through these interactions, KCTD9 participates in the ubiquitin-proteasome system and protein quality control pathways, influencing the turnover of proteins that may regulate cell proliferation, apoptosis, and signal transduction. The precise substrates and upstream regulatory signals of KCTD9 are not fully defined, making this knockout model a valuable tool for identifying novel interaction partners and delineating its role in protein homeostasis.
In ovarian cancer, aberrant ubiquitylation and proteasomal degradation can drive tumorigenesis by destabilizing tumor suppressors or stabilizing oncoproteins. KCTD9 may contribute to these processes, and its knockout in A2780 cells enables investigation of its involvement in ovarian cancer cell growth, survival, and chemosensitivity. This model allows researchers to directly assess how loss of KCTD9 affects ubiquitin-dependent proteostasis and downstream phenotypic outcomes in an epithelial ovarian cancer background.
The KCTD9 Knockout A2780 Polyclonal Cells support diverse experimental workflows, including western blotting, co-immunoprecipitation, and ubiquitination assays to examine KCTD9 complex formation and activity. Functional studies such as proliferation, colony formation, and apoptosis assays can delineate the role of KCTD9 in ovarian cancer cell behavior. Transcript analysis via RT-qPCR complements these approaches. The polyclonal population ensures that observed effects are representative of the knockout rather than clonal artifacts. For additional information, please contact Ascent Research.
